Why the study?
Coronary artery disease is a leading cause of death among cancer survivors, presenting specific clinical challenges and technical considerations when managing PCI in this growing population.
This review highlights the clinical challenges, outcomes, and technical considerations for managing coronary artery disease with PCI in the growing population of cancer survivors.
May support tailored PCI strategies in cancer survivors; leaves open need for prospective trials.
The number of cancer survivors in the United States is projected to increase by 31% by 2030. With advances in early screening, diagnosis and therapeutic strategies, a steadily increasing number of patients are surviving cancer. Coronary artery disease (CAD) is now one of the leading causes of death amongst cancer survivors, with the latter group of patients having a higher risk of CAD compared to the general population. Our review covers a range of specific challenges faced by doctors when considering percutaneous coronary interventions (PCI) in cancer patients; clinical outcomes in cancer patients undergoing PCI, as well as some important technical considerations to be made when making decisions regarding the management strategy in this special population of patients.
No takes yet. Share an insight, caveat, or question.
Doolub et al. (2022) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: